Navigation Links
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Date:12/29/2008

class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company have their first three microRNA-based tests, miRview(TM) squamous, miRview(TM) mets, and miRview(TM) meso, commercially available through its Philadelphia-based CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the timing of introduction of additional microRNA-based diagnostic tests, including miRview meso, miRview squamos and miRview mets, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those in
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , , BRISBANE, ... results from operations for the second quarter and six months ended June 30, ... of 2009 of $36.7 million, or $0.81 per share, compared with a net ... 2008. , , Dan Welch, Chairman, Chief Executive ...
... ... Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical ... Also Offers An Expanded Service Description For Each Of Its Three Major Business Divisions: ... ...
... , REDWOOD CITY, Calif., Aug. ... antibody therapeutics that target cancer stem cells, today announced the ... potent anti-cancer activity in colon and breast cancer models for ... of targeting cancer stem cells to treat solid tumors. ...
Cached Biology Technology:InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 3Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 4
(Date:4/24/2014)... very pleased to announce that it has assumed ownership ... the University of Wisconsin. , The Journal ... peer-reviewed journal that publishes papers on all aspects of ... the molecular to the ecological -- as well as ... to individuals and institutions, and it provides a reasonably ...
(Date:4/24/2014)... by fungus could now be treated in three days, rather ... scientists. , Cryptococcus a form of yeast ... medical research. They are found in many parts of ... mainly affect people with weakened immune systems. This infection kills ... team has tested the effects of the most commonly used ...
(Date:4/24/2014)... Carolina State University and the University of North Carolina ... that could help identify arterial plaque that is at ... or stroke. , At issue is the plaque that ... of plaque are deemed "vulnerable," meaning that they are ... cause heart attack or stroke. , "Existing state-of-the-art technologies ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... A team of researchers at the University of ... boardroom in an effort to build a business based ... The work of Claus Tittiger, professor of ... a highly competitive and intense National Science Foundation business-validation ...
... years of research at the Institute of Food Research, ... by food and drug companies worldwide. , IFR and ... secured funding from the Biotechnology and Biological Sciences Research ... to validate and improve how well it simulates the ...
... Pompeu Fabra University (Spain) have created a high resolution atlas ... The study demonstrates that an average image of an organ ... of comparing individual cases and differentiating healthy forms from pathologies. ... heart and its components such as the ventricles and ...
Cached Biology News:Insect research heads down path to start-up company with NSF I-Corps program 2Insect research heads down path to start-up company with NSF I-Corps program 3Commercial future for Model Gut 2An atlas of the human heart is drawn using statistics 2
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... EZ-Spread Plating Beads Sterile plating ... for glass rods and potentially hazardous ethanol flaming, ... Two choices of ready-to-use sterile packaging: dispenser bottle ... 50 plating, Fastest and easiest way ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
Biology Products: